Luyan Pharma Co.,Ltd.
Shenzhen Stock ExchangeTotal Valuation
Luyan Pharma Co.,Ltd. carries a market capitalization of 4.24B, placing it among publicly traded companies globally. Its enterprise value stands at 7.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.24B |
| Enterprise Value | 7.88B |
Share Statistics
Luyan Pharma Co.,Ltd. currently has 388.52M shares outstanding.
| Shares Outstanding | 388.52M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Luyan Pharma Co.,Ltd. trades at a trailing price-to-earnings ratio of 10.96. The price-to-sales ratio is 0.17, and the price-to-book ratio stands at 1.44.
| PE Ratio | 10.96 |
| PS Ratio | 0.17 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.33 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Luyan Pharma Co.,Ltd. trades at an EV/EBITDA multiple of 12.39 and an EV/FCF ratio of 17.31. The EV/Sales ratio of 0.38 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.39 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.38 |
| EV / EBITDA | 12.39 |
| EV / EBIT | 12.39 |
| EV / FCF | 17.31 |
Financial Position
Luyan Pharma Co.,Ltd. maintains a current ratio of 1.13, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 154.74, indicating elevated leverage, while an interest coverage ratio of 3.19 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.13 |
| Quick Ratio | 0.06 |
| Debt / Equity | 154.74 |
| Debt / EBITDA | 7.81 |
| Interest Coverage | 3.19 |
Financial Efficiency
Luyan Pharma Co.,Ltd. posts a return on equity of 13.29 and a return on invested capital of 5.93.
| Return on Equity (ROE) | 13.29 |
| Return on Assets (ROA) | 2.51 |
| Return on Invested Capital (ROIC) | 5.93 |
| Return on Capital Employed (ROCE) | 6.32 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 7.60 |
Taxes
Over the trailing twelve months, Luyan Pharma Co.,Ltd. has paid 101.07M in income taxes, reflecting an effective tax rate of 24.57.
| Income Tax | 101.07M |
| Effective Tax Rate | 24.57 |
Stock Price Statistics
Luyan Pharma Co.,Ltd.'s stock has gained approximately 24.97136% over the past 52 weeks. The 50-day moving average sits at 12.25, while the 200-day moving average is 13.52.
| Beta (5Y) | N/A |
| 52-Week Price Change | 24.97136% |
| 50-Day Moving Average | 12.25 |
| 200-Day Moving Average | 13.52 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached 635.69M, while operating income came in at 635.69M.
| Revenue | 20.56B |
| Gross Profit | 1.49B |
| Operating Income | 635.69M |
| Pretax Income | 411.45M |
| Net Income | 309.80M |
| EBITDA | 635.69M |
| EBIT | 635.69M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Luyan Pharma Co.,Ltd. holds 513.85M in cash and equivalents against 4.96B in total debt, resulting in a net debt position of 3.99B. Total book value stands at 2.36B, with working capital of 1.15B providing operational flexibility.
| Cash & Cash Equivalents | 513.85M |
| Total Debt | 4.96B |
| Net Debt | 3.99B |
| Equity (Book Value) | 2.36B |
| Book Value Per Share | 5.96 |
| Working Capital | 1.15B |
Cash Flow
After subtracting -304.40M in capital expenditures, free cash flow totaled -304.40M - equivalent to -0.77 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -304.40M |
| Free Cash Flow | -304.40M |
| FCF Per Share | -0.77 |
Margins
Luyan Pharma Co.,Ltd. operates with a gross margin of 7.26, reflecting its pricing power and cost economics. The operating margin of 3.09 and net profit margin of 1.51 provide insight into operational efficiency.
| Gross Margin | 7.26 |
| Operating Margin | 3.09 |
| Pretax Margin | 2.00 |
| Profit Margin | 1.51 |
| EBITDA Margin | 3.09 |
Dividends & Yields
The company's payout ratio of 102.70 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.81 |
| Dividend Yield | N/A |
| Payout Ratio | 102.70 |
| Shareholder Yield | 7.87 |
| FCF Yield | N/A |
Stock Splits
Luyan Pharma Co.,Ltd.'s most recent stock split took place on September 17, 2020 with a 1000:1073 split ratio.
| Last Split Date | 9/17/2020 |
| Split Ratio | 1000:1073 |
Scores
Luyan Pharma Co.,Ltd. posts an Altman Z-Score of 2.45, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.45 |